Invention Grant
- Patent Title: Chair ruthenium complexes and their use as anticancer agents
- Patent Title (中): 椅钌络合物及其作为抗癌剂的用途
-
Application No.: US12680661Application Date: 2008-07-21
-
Publication No.: US08357678B2Publication Date: 2013-01-22
- Inventor: Wenjie Mei
- Applicant: Wenjie Mei
- Applicant Address: CN Guangdong
- Assignee: Guangdong Pharmaceutical University
- Current Assignee: Guangdong Pharmaceutical University
- Current Assignee Address: CN Guangdong
- Agency: Sughrue Mion, PLLC
- Priority: CN200710030650 20070929
- International Application: PCT/CN2008/001347 WO 20080721
- International Announcement: WO2009/043223 WO 20090409
- Main IPC: A61K31/555
- IPC: A61K31/555 ; C07F15/00

Abstract:
The invention is reported a type of chair ruthenium complexes and their used as anticancer agent. The general formulae of these chair ruthenium complexes is: A-[Ru(bpy)2L](PF6)2, where in A is Δ or Λ, L is tFPIP, IPBP, IPBH or PYNI. These chair ruthenium complexes is characterized with that the center atom is ruthenium ion, the main ligand is 2-phenyl imidazole[4,5f][1,10]phenanthroline and its derivate, the co-ligand is two bipyridine, and the space structure is rigid octahedral. The complexes indicated by the invention are the chair isomer of all of these ruthenium complexes. This type of ruthenium complexes exhibit excellent inhibitory activity against liver cancer cell line BEL-7402, and can be used in preparing anticancer agent.
Public/Granted literature
- US20100216993A1 CHAIR RUTHENIUM COMPLEXES AND THEIR USE AS ANTICANCER AGENTS Public/Granted day:2010-08-26
Information query